ArticleCancer gene therapy2015
Isolation and characterization of progenitor mesenchymal cells in human pituitary tumors.
Article in Cancer gene therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- Article
- Enhanced EPR effects by tumour stromal cell mimicking nanoplatform on invasive pituitary adenoma.Materials today. Bio · 2024Article
- Identification and gene expression profiling of human gonadotrophic pituitary adenoma stem cells.Acta neuropathologica communications · 2023Article
- Article
- Influence of the Amount of Fresh Specimen on the Isolation of Tumor Mesenchymal Stem-Like Cells from High-Grade Glioma.Yonsei medical journal · 2021Article
- Up-regulation of sex-determining region Y-box 9 (SOX9) in growth hormone-secreting pituitary adenomas.BMC endocrine disorders · 2021Article
- Pituispheres Contain Genetic Variants Characteristic to Pituitary Adenoma Tumor Tissue.Frontiers in endocrinology · 2020Article
- Experimental Evidence and Clinical Implications of Pituitary Adenoma Stem Cells.Frontiers in endocrinology · 2020Review
- Mesenchymal Stem Cells from Nucleus Pulposus and Neural Differentiation Potential: a Continuous Challenge.Journal of molecular neuroscience : MN · 2019Article
- Pituitary adenomas, stem cells, and cancer stem cells: what's new?Journal of endocrinological investigation · 2018Review
- Stem/progenitor cells in pituitary organ homeostasis and tumourigenesis.The Journal of endocrinology · 2018Review
- Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas.Molecular neurobiology · 2017Article
- Regulation of pituitary stem cells by epithelial to mesenchymal transition events and signaling pathways.Molecular and cellular endocrinology · 2017Review
- Expression of Stem Cell Markers and Dopamine D2 Receptors in Human and Rat Prolactinomas.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- Effects of somatostatin and its analogues on progenitor mesenchymal cells isolated from human pituitary adenomas.Pituitary · 2017Article
- The identification of human pituitary adenoma-initiating cells.Acta neuropathologica communications · 2016Article
- Concise Review: Paracrine Role of Stem Cells in Pituitary Tumors: A Focus on Adamantinomatous Craniopharyngioma.Stem cells (Dayton, Ohio) · 2016Review
- Functional Characteristics of Multipotent Mesenchymal Stromal Cells from Pituitary Adenomas.Stem cells international · 2016Article
- THE EXPRESSION OF STEM CELL MARKERS (CD133, NESTIN, OCT4, SOX2) IN INVASIVE PITUITARY ADENOMAS.Acta endocrinologica (Bucharest, Romania : 2005)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Cancer Stem Cells (CSCs) theory suggests that genetic alterations in stem cells are the direct cause for cancer. The evidence for a CSC population that results in pituitary tumors is poor. Some studies report the isolation of CSCs, but a deep characterization of the stemness of these cells is lacking. Here, we report the isolation and detailed characterization of progenitor mesenchymal cells (PMCs) from both growth hormone-secreting (GH(+)) and non-secreting (NS) pituitary adenomas, determining the immunophenotype, the expression of genes related to stemness or to pituitary hormone cell types, and the differentiative potential towards osteo-, chondro- and adipogenic lineages. Finally, the expression of CD133, known as a marker for CSCs in other tumors, was analyzed. Isolated cells, both from GH(+) and NS tumors, satisfy all the criteria for the identification of PMCs and express known stem cell markers (OCT4, SOX2, KLF4, NANOG), but do not express markers of pituitary hormone cell types (PITX2, PROP1, PIT1). Finally, PMCs express CD133. We demonstrated that pituitary tumors contain a stem cell population that can generate cell types characteristic of mesenchymal stem cells, and express CD133, which is associated with CSCs in other tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.